4371-74-8

Usage

InChI:InChI=1/C15H28O4/c1-2-3-4-5-6-7-8-9-10-11-12-13(14(16)17)15(18)19/h13H,2-12H2,1H3,(H,16,17)(H,18,19)

Upstream product

• 7252-87-1 diethyl 2-dodecylmalonate 
• 143-15-7 1-dodecylbromide 
• 105-53-3 diethyl malonate 
• 67-56-1 methanol 
• 693244-98-3 methyl 2-trifluoromethyltetradecanoate 
• 4431-36-1 dodeca-2,4,6,8,10-pentaenylidene-malonic acid 
• 64-19-7 acetic acid 
• 15219-34-8 Oxalyl bromide 

Downstream Products

• 22141-28-2 hexadecane-2,3-dione 
• 22089-76-5 14,15-octacosanedione 
• 10192-32-2 1-tetracosene 

Relevant academic research and scientific papers

TRANSPORT DES CATIONS A TRAVERS DES MEMBRANES LIPIDIQUES BIMOLECULARES PAR DES NOUVEAUX MACROCYCLES DI ET TETRAESTERS POLYETHERES HYDROPHOBES

New hydrophobic polyether tetraesters substituted with carbon chains at C8 and C12 have the ability to transport selectively, but not very efficiently, the K(1+) and NH4(1+) ions.

Synthetic blocking reagents

The present invention concerns novel synthetic blocking reagents for the reduction of non-specific bindings in solid phase assays that rely on biological and specific recognition, e.g., in enzyme-linked immunosorbent assays (ELISAs). The invention provides the use of compounds as blocking reagents as well as kits comprising these compounds. The compounds comprise one or more poly(ethylene glycol) moieties, one or more alkyl- or aminoalkyl groups and another unit bridging the aforementioned groups, wherein the compound comprises at least one amino group.

New molecular markers for prostate tumor imaging: A study on 2-methylene substituted fatty acids as new AMACR inhibitors

The development of prostate carcinoma is associated with alterations in fatty acid metabolism. α-Methylacyl-CoA racemase (AMACR) is a peroxisomal and mitochondrial enzyme that catalyses interconversion between the (S)/(R)-isomers of a range of α-methylacyl-CoA thioesters. AMACR is involved in the β-oxidation of the dietary branched-chain fatty acids and bile acid intermediates. It is highly expressed in prostate (more than 95 %), colon (92 %), and breast cancers (44 %) but not in the respective normal or hyperplastic tissues. Thus, targeting of AMACR could be a new strategy for molecular imaging and therapy of prostate and some other cancers. Unlabeled 2-methylenacyl-CoA thioesters (12 a-c) were designed as AMACR binding ligands. The thioesters were tested for their ability to inhibit the AMACR-mediated epimerization of (25R)-THC-CoA and were found to be strong AMACR inhibitors. Radioiodinated (E)-131I-13-iodo-2-methylentridec-12-enoic acid ( 131I-7 c) demonstrated preferential retention in AMACR-positive prostate tumor cells (LNCaP, LNCaP C4-2wt and DU145) compared with both AMACR-knockout LNCaP C4-2 AMACR-siRNA and benign BPH1 prostate cell lines. A significant protein-bound radioactive fraction with main bands at 47 (sum of molecular weights of AMACR plus 12 c), 70, and 75 kDa was detected in LNCaP C4-2 wt cells. Copyright